Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock Holdings Lessened by Renaissance Technologies LLC

Renaissance Technologies LLC cut its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 17.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 201,500 shares of the biotechnology company’s stock after selling 43,100 shares during the period. Renaissance Technologies LLC owned about 0.14% of Aurinia Pharmaceuticals worth $1,151,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Cetera Advisors LLC grew its holdings in shares of Aurinia Pharmaceuticals by 18.9% during the first quarter. Cetera Advisors LLC now owns 60,139 shares of the biotechnology company’s stock valued at $301,000 after purchasing an additional 9,547 shares during the last quarter. GSA Capital Partners LLP grew its stake in Aurinia Pharmaceuticals by 196.1% during the 1st quarter. GSA Capital Partners LLP now owns 349,204 shares of the biotechnology company’s stock worth $1,750,000 after buying an additional 231,260 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Aurinia Pharmaceuticals by 15.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 38,952 shares of the biotechnology company’s stock worth $196,000 after buying an additional 5,079 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Aurinia Pharmaceuticals by 1.4% during the first quarter. Vanguard Group Inc. now owns 1,531,617 shares of the biotechnology company’s stock valued at $7,673,000 after acquiring an additional 21,119 shares during the period. Finally, Capstone Investment Advisors LLC acquired a new position in shares of Aurinia Pharmaceuticals during the first quarter valued at $158,000. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Up 1.4 %

Shares of AUPH stock opened at $7.12 on Friday. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.71 and a 1 year high of $10.05. The stock has a market cap of $1.02 billion, a PE ratio of -16.56 and a beta of 1.44. The business’s fifty day moving average is $6.52 and its 200-day moving average is $5.74. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.82 and a current ratio of 5.33.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.01. Aurinia Pharmaceuticals had a negative return on equity of 11.84% and a negative net margin of 24.31%. The company had revenue of $57.10 million for the quarter, compared to analysts’ expectations of $54.25 million. During the same period last year, the firm earned ($0.08) EPS. The firm’s revenue for the quarter was up 37.6% on a year-over-year basis. Equities analysts expect that Aurinia Pharmaceuticals Inc. will post 0.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on AUPH shares. HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Friday, September 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a report on Monday, September 16th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.00.

Insider Activity

In related news, insider Scott Michael Habig sold 18,249 shares of Aurinia Pharmaceuticals stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $5.31, for a total value of $96,902.19. Following the transaction, the insider now directly owns 456,338 shares in the company, valued at $2,423,154.78. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 4.30% of the stock is owned by insiders.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.